

RESPONSE TO RESTRICTION REQUIREMENT
U.S. Application No. 10/585,863 (Q95957)

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A ~~recombinant-variant of the~~ Moloney murine leukemia virus reverse transcriptase ~~of SEQ ID NO:2~~, wherein the ~~glutamine-amino acid at the-position 84 of 84th-amino acid from the N-terminus~~, is replaced with amino acid X, which is an amino acid with a side chain shorter than that of glutamine.

2. (Currently Amended) The reverse transcriptase of claim 1, wherein the ~~aspartic acid~~asparagine at the-position ~~524 of 524th-amino acid~~, is replaced with amino acid ~~asparagine~~aspartic acid.

3. (Currently Amended) The reverse transcriptase of claim 1, wherein the amino acid X is alanine, serine, aspartic acid or ~~asparagine~~asparagine.

4. (Original) The reverse transcriptase of claim 3, wherein the amino acid X is alanine.

RESPONSE TO RESTRICTION REQUIREMENT
U.S. Application No. 10/585,863 (Q95957)

5. (Currently Amended) ~~The sequence~~ A nucleic acid molecule encoding the reverse transcriptase of claim 1.

6. (Currently Amended) A method for expressing ~~the~~ a recombinant murine leukemia virus (MLV) reverse transcriptase, said method comprising the steps of:

a) transforming an ~~In this method, the~~ expression vector carrying the coding sequence of ~~the~~ said reverse transcriptase ~~is transformed into~~ E. coli;

b) selecting positive ~~Positive clones are picked to that~~ express ~~the said recombinant~~ reverse transcriptase; and

c) culturing said positive clones to express said reverse transcriptase,
wherein ~~The said reverse transcriptase is a variant of referred to as the~~ MLV reverse transcriptase of SEQ ID NO:2, wherein the amino acid at ~~with the glutamine at the position 84 of~~ the 84th amino acid replaced with is amino acid X, which is an amino acid with side chain shorter than that of glutamine.

7. (Currently Amended) The method of claim 6, wherein the amino acid ~~aspartic acid~~ asparagine at the position ~~524 of~~ 524th ~~amino acid from the N-terminus is replaced with~~ asparagine ~~aspartic acid~~.

8. (Original) The method of claim 7, wherein the amino acid X is alanine.

RESPONSE TO RESTRICTION REQUIREMENT
U.S. Application No. 10/585,863 (Q95957)

9. (Currently Amended) The method of claim 8, wherein said reverse transcriptase is expressed by the sequence of the expression plasmid having the sequence according to SEQ ID NO: 1 is listed in table 1.

10. (Currently Amended) The methods of claim 6, wherein ~~the~~ said E. coli strain is BL21.

11. (Currently Amended) The methods of claim 7, wherein ~~the~~ said E. coli strain is BL21.

12. (Currently Amended) The methods of claim 8, wherein ~~the~~ said E. coli strain is BL21.

13. (Cancelled).

14. (Currently Amended) The reverse transcriptase of claim 2, wherein the amino acid X is alanine, serine, aspartic acid, ~~asparagine~~ asparagine.

15. (Currently Amended) The reverse transcriptase of claim 14, wherein the amino acid ~~X~~ is alanine.

RESPONSE TO RESTRICTION REQUIREMENT
U.S. Application No. 10/585,863 (Q95957)

16. (New) A variant of the wild type Moloney murine leukemia virus reverse transcriptase, wherein said wild type Moloney murine leukemia virus reverse transcriptase has the amino acid sequence of SEQ ID NO:9, wherein said variant has an amino acid mutation at position 84 such that the glutamine is replaced with amino acid X, wherein said amino acid X is an amino acid with side chain shorter than that of glutamine.